For patients with advanced or metastatic disease, HER2 positivity is a key biomarker, identifying those who may benefit from trastuzumab in combination with chemotherapy, which has been shown to improve OS, and testing for HER2 is standard of care for this patient cohort [12]. Here, ERBB2 is linked to metastatic neoplasm.